Challenges in Drug Design
Any drug that is taken undergoes a number of chemical reactions in the liver as the body attempts to neutralize foreign substances. This set of reactions is well characterized, and a great deal of knowledge exists as to how drugs are modified as the body eliminates them. More importantly, various chemical structures are highly toxic to biological systems, and these are also well characterized. These constraints must also be taken under consideration as novel drugs are developed. The annual decline in the number of drugs approved for release onto the market in recent years has put pressure on you and your team to refine the drug discovery process and use more effective methods to discover a higher number of successful lead compounds.
Drug Design is an extraordinary inventive process of new medication on the basis of biological target. Drug Discovery Informatics Market size was USD 1.6 billion in 2015 and is forecast to reach around USD 6.5 billion by 2023. In 2012 total market for Drug Discovery Informatics was around in between 400 to 500 million, and is familiar to reach around more than 3,500 million in 2022.
- Structure based strategies
- Carbon nano tubes (CNTS)
- parallel drug designs
Related Conference of Challenges in Drug Design
Challenges in Drug Design Conference Speakers
Recommended Sessions
- Advances in BABE
- Assessment of Bioequivalence
- BA/BE of Biologics & Biosimilars
- Bioavailability Studies
- Bioequivalence Protocols : In vivo/ In vitro studies
- Bioequivalence Studies
- Challenges in Drug Design
- Challenges in Drug Development
- Clinical Pharmacology and Therapeutics
- Clinical Trials
- Contract Research Organizations
- Factors Affecting Bioavailability
- Managing BA/BE Studies
- Nutrient Bioavailability
- Pharma Clinical Trials
- Pharmaceutical Industry: Entrepreneurs Investment Meet
- Regulatory Requirements for Bioequivalence
- Significance of BA/BE Studies
- Study Designs